Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | SRD5A1 | P18405 | 18/20 | 0.59 |
| ▸ | SRD5A2 | P31213 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080151 | 0.79 | AR (1.00) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL5241935 | 0.79 | AR (1.00) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL917931 | 0.79 | AR (1.00) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL917557 | 0.75 | SRD5A1 (0.46) | SRD5A1SRD5A2 | |
| SCHEMBL916376 | 0.72 | SRD5A1 (0.49) | SRD5A1SRD5A2 | |
| SCHEMBL5215064 | 0.72 | AR (0.84) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL7080869 | 0.72 | AR (0.84) | ARSRD5A1SRD5A2LMNAABCB11 | |
| SCHEMBL18121305 | 0.72 | SRD5A1 (0.85) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| SCHEMBL10000656 | 0.72 | SRD5A1 (0.85) | SRD5A1SRD5A2LMNAABCB11GLRA1 | |
| SCHEMBL917112 | 0.71 | AR (0.79) | ARSRD5A1SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371367-A1 | Method of treating men with testosterone supplement and 5alpha reductase inhibitor | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2305352-A1 | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders | Merck Sharp & Dohme Corp. (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MEEHAN ALAN | 2011-01-20 | — | — | US | disclosed |
| EP-1734963-A4 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MERCK & CO INC (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1734963-A2 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | Merck & Co., Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097127-A2 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015164-A1 | METHOD OF TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS | CYP17A1, SHBG, CYP21A2 | AR 12/4885SRD5A1 10/4885SRD5A2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.